Slide 01 SMART 5-Year Data
Demonstrates
Long-Term
Relief
SMART 5-Year Data Demonstrates Long-Term Relief
Slide 02 SMART 5-Year Data
Demonstrates
Long-Term
Relief
SMART 5-Year Data Demonstrates Long-Term Relief
Slide 03 SMART 5-Year Data
Demonstrates
Long-Term
Relief
SMART 5-Year Data Demonstrates Long-Term Relief
Slide 04 in Chronic Vertebrogenic
Low Back Pain
Vertebral
Endplates
The Role of in Chronic Vertebrogenic Low Back Pain Vertebral Endplates The Role of
Slide 05 for the Relief of Chronic
Vertebrogenic Low Back Pain
The Intracept
Procedure
The Intracept Procedure for the Relief of Chronic Vertebrogenic
Low Back Pain
Slide 06 Relievant’s New
Patient Education Website
Visit
Intracept.com
Visit Intracept.com Relievant’s New
Patient Education Website

We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2

Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible.

The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body.

Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept, commercially available in the US, is supported by two Level I randomized controlled trials in addition to long-term durability data showing functional and pain improvements are maintained beyond 5 years.

We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2

Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible.

The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body.

Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept, commercially available in the US, is supported by two Level I randomized controlled trials in addition to long-term durability data showing functional and pain improvements are maintained beyond 5 years.

“The Intracept Procedure is a new, minimally invasive option to treat chronic vertebrogenic low back pain. The procedure has been proven to be safe and effective in clinical trials, and is much less invasive than typical surgical options to treat vertebrogenic pain.”

Jeffrey Fischgrund, MD, Chairman, Department of Orthopedics, Beaumont Hospital, Royal Oak and principal investigator of the SMART Trial

“The Intracept Procedure is a new, minimally invasive option to treat chronic vertebrogenic low back pain. The procedure has been proven to be safe and effective in clinical trials, and is much less invasive than typical surgical options to treat vertebrogenic pain.”

Jeffrey Fischgrund, MD, Chairman, Department of Orthopedics, Beaumont Hospital, Royal Oak and principal investigator of the SMART Trial